Lessons from recent investigator-initiated trials of gene-editing therapies in China

Li Du, Kalina Kamenova, Zhangyu Wang, Meng Wang, Yujuan Li, Ruipeng Lei, Xi Zhang
Nature Medicine · Springer Nature · 2026-11-11 · DOI: 10.1038/s41591-026-04768-x

Аннотация

Nature Medicine, Published online: 11 November 2026; doi:10.1038/s41591-026-04768-x Several deaths during trials of experimental cell and gene therapies in China appear to reveal gaps in governance and oversight. A new layer of independent external review is needed for clinical supervision of high-risk therapies.

Читать у издателя →

Похожие статьи